DE
Therapeutic Areas
Eleva Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Factor H (CPV-104) | Complement Disorders | Phase 1 |
| Undisclosed Program | Complement-driven diseases / Dry AMD | Phase 1 |
Leadership Team at Eleva
BC
Björn Cochlovius, Ph.D., Assoc. Prof.
Chief Executive Officer & Managing Director
DA
Dr. Andreas Schaaf, Ph.D.
Chief Scientific Officer & Managing Director
DS
Donato Spota, M.Sc.
Chief Financial Officer & Managing Director
DM
Dr. Martin Bauer, MD, FNWC
Chief Medical Officer (external)